Provided by Tiger Trade Technology Pte. Ltd.

Eli Lilly

999.84
-1.5100-0.15%
Post-market: 995.01-4.8300-0.48%19:59 EDT
Volume:1.45M
Turnover:1.44B
Market Cap:945.23B
PE:43.57
High:1,002.93
Open:1,000.03
Low:990.30
Close:1,001.35
52wk High:1,133.95
52wk Low:623.78
Shares:945.38M
Float Shares:945.00M
Volume Ratio:0.56
T/O Rate:0.15%
Dividend:6.23
Dividend Rate:0.62%
EPS(TTM):22.95
EPS(LYR):22.95
ROE:101.16%
ROA:19.42%
PB:35.62
PE(LYR):43.57

Loading ...

CMS Names Pfizer, Eli Lilly, and AbbVie Drugs for Third Medicare Price Talks

TIPRANKS
·
Jan 28

Medpal AI Plc - Unit Approved to Purchase Eli Lilly Products in UK

THOMSON REUTERS
·
Jan 28

Medpal AI Plc - to Dispense Eli Lilly's Mounjaro in UK

THOMSON REUTERS
·
Jan 28

US names HIV, arthritis drugs for next Medicare price talks

Reuters
·
Jan 28

CMS: Drugs Selected for Third Cycle of Medicare Drug Price Negotiation Are Rexulti, Trulicity, Verzenio, Xeljanz; Xeljanz Xr and Xolair

THOMSON REUTERS
·
Jan 28

Eli Lilly & Co. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
Jan 28

Eli Lilly's Jaypirca Gets Approval in Canada for Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia

MT Newswires Live
·
Jan 28

Citigroup Maintains Street-High $1,500 Price Target on Eli Lilly Stock (LLY)

TIPRANKS
·
Jan 28

Eli Lilly’s Pirtobrutinib Trial Completion Signals Next Phase in the BTK Inhibitor Race

TIPRANKS
·
Jan 28

Jaypirca® (Pirtobrutinib), the First and Only Non-Covalent (Reversible) Btk Inhibitor, NOW Available in Canada for Adult Patients With Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

THOMSON REUTERS
·
Jan 27

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Pennant Group (PNTG) and Warby Parker (WRBY)

TIPRANKS
·
Jan 27

Roche's CT-388 Could Compete With Lilly's Zepbound on Obesity Efficacy -- Market Talk

Dow Jones
·
Jan 27

Roche obesity drug shows 22.5% weight loss as it seeks to catch up with Lilly, Novo

Reuters
·
Jan 27

Rothschild & Co. Redburn Adjusts PT on Eli Lilly and Co. to $830 From $775, Maintains Neutral Rating

MT Newswires Live
·
Jan 27

Eli Lilly’s (LLY) New Marketing Focuses on ‘Weight Stigma’

TIPRANKS
·
Jan 26

Truist Financial Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

TIPRANKS
·
Jan 26

Eli Lilly Advances Remternetug Delivery Options With Completed Device Study

TIPRANKS
·
Jan 24

Bernstein Sees Eli Lilly Stock (LLY) Hitting $1,300 Per Share

TIPRANKS
·
Jan 23

Eli Lilly, Novo Nordisk Set for Fierce Battle in India’s Obesity Drug Market as Sun Pharma Wins Wegovy Generic Nod

TIPRANKS
·
Jan 23

Indian drugmakers get regulatory nod to sell generic Wegovy, heating obesity‑drug race

Reuters
·
Jan 23